Earnings ·
Geron reports Q3 net income of $1.4 million on RYTELO revenue of $60.1 million
GERNGeron Corp
Geron Corporation reported a net income of $1.4 million, or $0.00 per share, for the third quarter ended September 30, 2026, compared to a net loss of $18.4 million in the prior-year period. Total product revenue reached $60.1 million, driven by RYTELO (imetelstat) sales, representing a 5% increase from the second quarter and a 27% rise year-over-year. The company lowered its full-year 2026 total operating expense guidance to $220 million–$230 million while maintaining revenue expectations at the mid-to-high end of the $220 million–$240 million range. Geron also announced the discontinuation of the Phase 3 IMpactMF trial for myelofibrosis and initiated a gated commercial launch in targeted European markets, with Germany availability expected by year-end. The company ended the quarter with approximately $339 million in cash and marketable securities. Geron is a hematology-focused biopharmaceutical company developing treatments for blood cancers.